ParkinsonCanadaV1, Main, Exploration, bibRecord, 001D06

Impulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients

Identifieur interne : 001D06 ( Main/Exploration ); précédent : 001D05; suivant : 001D07

Impulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients

Auteurs : Daniel Weintraub [États-Unis] ; Juergen Koester [Allemagne] ; Marc N. Potenza [États-Unis] ; Andrew D. Siderowf [États-Unis] ; Mark Stacy [États-Unis] ; Valerie Voon [Canada] ; Jacqueline Whetteckey [États-Unis] ; Glen R. Wunderlich [Canada] ; Anthony E. Lang [Canada]

Source :

Archives of neurology : (Chicago) [ 0003-9942 ] ; 2010.

RBID : Pascal:10-0257883

Descripteurs français

Pascal (Inist)
- Trouble du contrôle des impulsions, Maladie de Parkinson, Pathologie du système nerveux, Etude transversale, Homme.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Cross sectional study, Human, Impulse control disorder, Nervous system diseases, Parkinson disease.

Abstract

Context: An association between dopamine-replacement therapies and impulse control disorders (ICDs) in Parkinson disease (PD) has been suggested in preliminary studies. Objectives: To ascertain point prevalence estimates of 4 ICDs in PD and examine their associations with dopamine-replacement therapies and other clinical characteristics. Design: Cross-sectional study using an a priori established sampling procedure for subject recruitment and raters blinded to PD medication status. Patients: Three thousand ninety patients with treated idiopathic PD receiving routine clinical care at 46 movement disorder centers in the United States and Canada. Main Outcome Measures: The Massachusetts Gambling Screen score for current problem/pathological gambling, the Minnesota Impulsive Disorders Interview score for compulsive sexual behavior and buying, and Diagnostic and Statistical Manual of Mental Disorders research criteria for binge-eating disorder. Results: An ICD was identified in 13.6% of patients (gambling in 5.0%, compulsive sexual behavior in 3.5%, compulsive buying in 5.7%, and binge-eating disorder in 4.3%), and 3.9% had 2 or more ICDs. Impulse control disorders were more common in patients treated with a dopamine agonist than in patients not taking a dopamine agonist (17.1% vs 6.9%; odds ratio [OR], 2.72; 95% confidence interval [CI], 2.08-3.54; P<.001). Impulse control disorder frequency was similar for pramipexole and ropinirole (17.7% vs 15.5%; OR, 1.22; 95% CI, 0.94-1.57; P=.14). Additional variables independently associated with ICDs were levodopa use, living in the United States, younger age, being unmarried, current cigarette smoking, and a family history of gambling problems. Conclusions: Dopamine agonist treatment in PD is associated with 2- to 3.5-fold increased odds of having an ICD. This association represents a drug class relationship across ICDs. The association of other demographic and clinical variables with ICDs suggests a complex relationship that requires additional investigation to optimize prevention and treatment strategies.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000437
to stream PascalFrancis, to step Curation: 000840
to stream PascalFrancis, to step Checkpoint: 000344
to stream Main, to step Merge: 001E34
to stream Main, to step Curation: 001D06

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Impulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients</title>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Philadelphie</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Philadelphia Veterans Affairs Medical Center</s1>
<s2>Philadelphia</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Philadelphie</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Koester, Juergen" sort="Koester, Juergen" uniqKey="Koester J" first="Juergen" last="Koester">Juergen Koester</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Boehringer Ingelheim Pharma GmbH & Co KG</s1>
<s2>Ingelheim</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Ingelheim</wicri:noRegion>
<wicri:noRegion>Boehringer Ingelheim Pharma GmbH & Co KG</wicri:noRegion>
<wicri:noRegion>Boehringer Ingelheim Pharma GmbH & Co KG</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Yale University School of Medicine</s1>
<s2>New Haven, Connecticut</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Philadelphie</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Duke University Medical Center</s1>
<s2>Durham, North Carolina</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name>
<affiliation wicri:level="4"><inist:fA14 i1="06"><s1>University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Whetteckey, Jacqueline" sort="Whetteckey, Jacqueline" uniqKey="Whetteckey J" first="Jacqueline" last="Whetteckey">Jacqueline Whetteckey</name>
<affiliation wicri:level="2"><inist:fA14 i1="07"><s1>Boehringer Ingelheim Pharmaceuticals Inc</s1>
<s2>Ridgefield, Connecticut</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wunderlich, Glen R" sort="Wunderlich, Glen R" uniqKey="Wunderlich G" first="Glen R." last="Wunderlich">Glen R. Wunderlich</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Boehringer Ingelheim (Canada) Ltd</s1>
<s2>Burlington, Ontario</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Boehringer Ingelheim (Canada) Ltd</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="4"><inist:fA14 i1="06"><s1>University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0257883</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0257883 INIST</idno>
<idno type="RBID">Pascal:10-0257883</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000437</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000840</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000344</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000344</idno>
<idno type="wicri:doubleKey">0003-9942:2010:Weintraub D:impulse:control:disorders</idno>
<idno type="wicri:Area/Main/Merge">001E34</idno>
<idno type="wicri:Area/Main/Curation">001D06</idno>
<idno type="wicri:Area/Main/Exploration">001D06</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Impulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients</title>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Philadelphie</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Philadelphia Veterans Affairs Medical Center</s1>
<s2>Philadelphia</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Philadelphie</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Koester, Juergen" sort="Koester, Juergen" uniqKey="Koester J" first="Juergen" last="Koester">Juergen Koester</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Boehringer Ingelheim Pharma GmbH & Co KG</s1>
<s2>Ingelheim</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Ingelheim</wicri:noRegion>
<wicri:noRegion>Boehringer Ingelheim Pharma GmbH & Co KG</wicri:noRegion>
<wicri:noRegion>Boehringer Ingelheim Pharma GmbH & Co KG</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Yale University School of Medicine</s1>
<s2>New Haven, Connecticut</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Philadelphie</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Duke University Medical Center</s1>
<s2>Durham, North Carolina</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name>
<affiliation wicri:level="4"><inist:fA14 i1="06"><s1>University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Whetteckey, Jacqueline" sort="Whetteckey, Jacqueline" uniqKey="Whetteckey J" first="Jacqueline" last="Whetteckey">Jacqueline Whetteckey</name>
<affiliation wicri:level="2"><inist:fA14 i1="07"><s1>Boehringer Ingelheim Pharmaceuticals Inc</s1>
<s2>Ridgefield, Connecticut</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wunderlich, Glen R" sort="Wunderlich, Glen R" uniqKey="Wunderlich G" first="Glen R." last="Wunderlich">Glen R. Wunderlich</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Boehringer Ingelheim (Canada) Ltd</s1>
<s2>Burlington, Ontario</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Boehringer Ingelheim (Canada) Ltd</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="4"><inist:fA14 i1="06"><s1>University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Archives of neurology : (Chicago)</title>
<title level="j" type="abbreviated">Arch. neurol. : (Chic.)</title>
<idno type="ISSN">0003-9942</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Archives of neurology : (Chicago)</title>
<title level="j" type="abbreviated">Arch. neurol. : (Chic.)</title>
<idno type="ISSN">0003-9942</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cross sectional study</term>
<term>Human</term>
<term>Impulse control disorder</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Trouble du contrôle des impulsions</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Etude transversale</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Context: An association between dopamine-replacement therapies and impulse control disorders (ICDs) in Parkinson disease (PD) has been suggested in preliminary studies. Objectives: To ascertain point prevalence estimates of 4 ICDs in PD and examine their associations with dopamine-replacement therapies and other clinical characteristics. Design: Cross-sectional study using an a priori established sampling procedure for subject recruitment and raters blinded to PD medication status. Patients: Three thousand ninety patients with treated idiopathic PD receiving routine clinical care at 46 movement disorder centers in the United States and Canada. Main Outcome Measures: The Massachusetts Gambling Screen score for current problem/pathological gambling, the Minnesota Impulsive Disorders Interview score for compulsive sexual behavior and buying, and Diagnostic and Statistical Manual of Mental Disorders research criteria for binge-eating disorder. Results: An ICD was identified in 13.6% of patients (gambling in 5.0%, compulsive sexual behavior in 3.5%, compulsive buying in 5.7%, and binge-eating disorder in 4.3%), and 3.9% had 2 or more ICDs. Impulse control disorders were more common in patients treated with a dopamine agonist than in patients not taking a dopamine agonist (17.1% vs 6.9%; odds ratio [OR], 2.72; 95% confidence interval [CI], 2.08-3.54; P<.001). Impulse control disorder frequency was similar for pramipexole and ropinirole (17.7% vs 15.5%; OR, 1.22; 95% CI, 0.94-1.57; P=.14). Additional variables independently associated with ICDs were levodopa use, living in the United States, younger age, being unmarried, current cigarette smoking, and a family history of gambling problems. Conclusions: Dopamine agonist treatment in PD is associated with 2- to 3.5-fold increased odds of having an ICD. This association represents a drug class relationship across ICDs. The association of other demographic and clinical variables with ICDs suggests a complex relationship that requires additional investigation to optimize prevention and treatment strategies.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Canada</li>
<li>États-Unis</li>
</country>
<region><li>Caroline du Nord</li>
<li>Connecticut</li>
<li>Ontario</li>
<li>Pennsylvanie</li>
</region>
<settlement><li>Philadelphie</li>
<li>Toronto</li>
</settlement>
<orgName><li>Université de Toronto</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
</region>
<name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name>
<name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name>
<name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
<name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<name sortKey="Whetteckey, Jacqueline" sort="Whetteckey, Jacqueline" uniqKey="Whetteckey J" first="Jacqueline" last="Whetteckey">Jacqueline Whetteckey</name>
</country>
<country name="Allemagne"><noRegion><name sortKey="Koester, Juergen" sort="Koester, Juergen" uniqKey="Koester J" first="Juergen" last="Koester">Juergen Koester</name>
</noRegion>
</country>
<country name="Canada"><region name="Ontario"><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name>
</region>
<name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<name sortKey="Wunderlich, Glen R" sort="Wunderlich, Glen R" uniqKey="Wunderlich G" first="Glen R." last="Wunderlich">Glen R. Wunderlich</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D06 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D06 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:10-0257883
   |texte=   Impulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Impulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients

Impulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri